Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma, like GSK’s ovarian cancer med ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

Roche is handing over $595 million to bolster its Foundation Medicine business with a deal to snap up SAGA Diagnostics. | ...

In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...

| Bioprocessing is evolving rapidly in a shifting landscape of innovative and complex products, processes and technologies.

A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the ...

Twelve months after releasing a roadmap to shift away from animal testing requirements, the FDA has declared mission ...